News

Exai Bio Announces Publication in Nature Communications Highlighting its Generative AI Liquid Biopsy Platform

Exai Bio, a next-generation oncRNA- and generative AI-based liquid biopsy company, today announced a peer-reviewed publication about its generative AI model in Nature Communications. The paper entitled “Deep generative AI models analyzing circulating orphan non-coding RNAs enable detection of early...

UCSF Joins I-Corps’ New Regional Innovation Hub for the Northwest

Training will help entrepreneurs at UCSF develop their ideas into companies. UC San Francisco is part of a new Northwest Region Innovation Corps (I-Corps) Hub funded by the National Science Foundation to train faculty and student entrepreneurs on how to commercialize their research. ...

Delve Bio and UCSF Publish Research Demonstrating Clinical Utility of Metagenomic Next-Generation Sequencing (mNGS) for Diagnosing Serious Neurological Infections

Delve Bio, a pioneer in metagenomic next-generation sequencing (mNGS) for infectious diseases, in collaboration with the University of California, San Francisco (UCSF), today announced Nature Medicine has published its study demonstrating the clinical utility of mNGS testing to identify difficult-...

Enlaza Therapeutics marries covalent and biologic drugs

While they were both still at Nerio Therapeutics, Sergio Duron brought Sandy Madigan a promising paper from the laboratory of Lei Wang, a chemical biologist at the University of California, San Francisco. It described an unnatural amino acid that can turn a protein into a covalent binder.

Female Founders Social Event

UCSF Innovation Ventures Engagement & Opportunity Development and Licensing Teams organized and hosted a networking event designed to connect UCSF’s current and upcoming female founders with entrepreneurs who support them.

Minutia: Shifting the T1D Paradigm

UCSF Innovation Ventures Engagement & Opportunity Development and Licensing Teams organized and hosted a panel discussion entitled “Translating UCSF research into human therapeutics. Minutia: Shifting the T1D Paradigm on October 23, 2024.

BeeKeeperAI and Topcon Team Up to Accelerate Healthcare from the Eye

BeeKeeperAI, a pioneer in privacy-enhancing, multi-party collaboration software for artificial intelligence (AI) development and deployment, and Topcon Healthcare, a leading provider of medical devices and software solutions including advanced multi-modal imaging, vendor-inclusive data management,...

Neuvivo Seeks FDA Approval for Its Breakthrough ALS Treatment

Neuvivo, a late-clinical stage biopharmaceutical company, today announced it submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for NP001 (sodium chlorite infusion) to treat amyotrophic lateral sclerosis (ALS). NP001 is an investigational treatment that, if...

Cardiology Panel Focused on the University’s Expertise

Cardiovascular disease remains the nation’s leading cause of death, and the UCSF Cardiology Department of Medicine is a pioneer in developing better ways to prevent, diagnose, and treat heart disease. Our mission is to provide the best possible care to all patients with cardiovascular disease, make...

PreludeDx Announces Groundbreaking Study Results on HER2-Positive DCIS Patients

Prelude Corporation, a leader in precision diagnostics for early-stage breast cancer, today announced the results of a cutting-edge study in Clinical Breast Cancer. The study marks a significant advancement in personalized treatment for DCIS patients. Prelude is a UCSF start-up from the lab of...